United States · FDA National Drug Code directory
Erlotinib
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 68382-913_e34fafdf-2fda-4031-9202-6d7e85925dc1
- Product NDC
- 68382-913
- Form
- TABLET
- Composition / generic term
- Erlotinib
- Labeler
- Zydus Pharmaceuticals USA Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20200430
- Source listing expiry
- 20261231
Source-listed ingredients
- ERLOTINIB HYDROCHLORIDE — 25 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET in 1 BOTTLE (68382-913-06) · 68382-913-06
- 90 TABLET in 1 BOTTLE (68382-913-16) · 68382-913-16
- 3 BLISTER PACK in 1 CARTON (68382-913-84) / 10 TABLET in 1 BLISTER PACK (68382-913-30) · 68382-913-84
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →